With the concept that low expression of RBP7 leads to poor prognosis of ER+ breast cancer patients, we further performed KEGG pathway analysis in ER+ breast cancer and found that RBP7 exerts its biological function through crosstalk with the PPAR and PI3K/AKT signalling pathways. Here, AKT1 is linked to breast carcinoma.